These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9701357)

  • 21. MDR1 inhibition: less resistance or less relevance?
    Garraway LA; Chabner B
    Eur J Cancer; 2002 Dec; 38(18):2337-40. PubMed ID: 12460776
    [No Abstract]   [Full Text] [Related]  

  • 22. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of drug efflux pumps in acute myeloid leukemia.
    van der Kolk DM; de Vries EG; Müller M; Vellenga E
    Leuk Lymphoma; 2002 Apr; 43(4):685-701. PubMed ID: 12153153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Pros and cons" on how to measure multidrug resistance in leukemias.
    Kappelmayer J; Karászi E; Telek B; Jakab K
    Leuk Lymphoma; 2002 Apr; 43(4):711-7. PubMed ID: 12153155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of MDR-1 in refractory lymphoma.
    Sandor V; Wilson W; Fojo T; Bates SE
    Leuk Lymphoma; 1997 Dec; 28(1-2):23-31. PubMed ID: 9498700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: How does the MRP/GS-X pump export doxorubicin?
    Broxterman HJ; Heijn M; Lankelma J
    J Natl Cancer Inst; 1996 Apr; 88(7):466-8. PubMed ID: 8618244
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeted doxorubicin-liposomes as a tool to circumvent P-gp-mediated resistance in ovarian carcinoma cells.
    Krieger ML; Konold A; Wiese M; Jaehde U; Bendas G
    Int J Clin Pharmacol Ther; 2010 Jul; 48(7):442-4. PubMed ID: 20557838
    [No Abstract]   [Full Text] [Related]  

  • 28. Anthracycline resistance in breast cancer: clinical applications of current knowledge.
    Ravdin PM
    Eur J Cancer; 1995; 31A Suppl 7():S11-4. PubMed ID: 8562184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are ABCB1 (P-glycoprotein) polymorphisms clinically relevant in ovarian cancer? - Finally an Answer!
    Konecny GE
    Gynecol Oncol; 2013 Oct; 131(1):1-2. PubMed ID: 24093937
    [No Abstract]   [Full Text] [Related]  

  • 30. Multidrug resistance in the chronic lymphoproliferative disorders.
    Drain S; Catherwood MA; Alexander HD
    Leuk Lymphoma; 2010 Oct; 51(10):1793-804. PubMed ID: 20615085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidrug resistance in breast cancer--is the jury in yet?
    Kaye SB
    J Natl Cancer Inst; 1997 Jul; 89(13):902-3. PubMed ID: 9214663
    [No Abstract]   [Full Text] [Related]  

  • 32. Indirect mechanism of drug transport by P-glycoprotein.
    Roepe PD
    Trends Pharmacol Sci; 1994 Dec; 15(12):445-6. PubMed ID: 7886815
    [No Abstract]   [Full Text] [Related]  

  • 33. 'Rapping' on the door of drug resistance.
    Rund D
    Leuk Lymphoma; 2009 Jul; 50(7):1065-6. PubMed ID: 19557625
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of ATP-binding cassette transporters and clinical implications.
    Cascorbi I; Haenisch S
    Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response.
    Wada M
    Cancer Lett; 2006 Mar; 234(1):40-50. PubMed ID: 16377077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of P-glycoprotein in drug resistance in multiple myeloma.
    Abraham J; Salama NN; Azab AK
    Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells.
    Chen XP; Wang Q; Guan J; Huang ZY; Zhang WG; Zhang BX
    World J Gastroenterol; 2006 Jun; 12(21):3332-7. PubMed ID: 16733848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction?
    McLeod HL
    Eur J Cancer; 1994; 30A(14):2039-41. PubMed ID: 7857699
    [No Abstract]   [Full Text] [Related]  

  • 40. Re: Circumvention of multi-drug resistance with anti-P-glycoprotein antibodies: clinical potential or experimental artifact?
    Baccarani M
    J Natl Cancer Inst; 1995 Jun; 87(11):845-6. PubMed ID: 7791235
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.